Caffree
Seattle, US · Founded 2023 · Delaware corporation · 2 known investors
Caffree develops a powdered enzymatic system for precision decaffeination that converts caffeine into theobromine, allowing coffee brands to control caffeine levels without changing flavor. It targets coffee brands, cold brew and RTD beverage manufacturers, and co-packers, integrating into existing production equipment.
BiotechDeep TechFoodTech
Founders & leadership
ES
Eric Steven QuickExecutive
AG
Aryeh GanzNamed on SEC filing
Board
FC
Frank CurzioBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 1 round · 2026
▶$4.9MraisedApr 2026 · 20 investors · OtherRule 506(b)
▶$4.9MraisedApr 2026 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Aryeh GanzExecutive Officer, Director, Promoter
- Eric Steven QuickExecutive Officer, Director
- Frank CurzioDirector
- Offering amount
- $7.9M
- Amount sold
- $4.9M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Caffree do?
- Caffree develops a powdered enzymatic system for precision decaffeination that converts caffeine into theobromine, allowing coffee brands to control caffeine levels without changing flavor. It targets coffee brands, cold brew and RTD beverage manufacturers, and co-packers, integrating into existing production equipment.
- Who are Caffree's investors?
- Caffree's investors include Baruch Future Ventures, Cornucopian Capital Management.
- How much funding has Caffree raised?
- Caffree has disclosed $4.9M raised across 1 round.
- Where is Caffree headquartered?
- Caffree is headquartered in Seattle, US.